Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)

NCT06304168 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06304168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06304168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
May 13, 2019
Completion date
May 15, 2028
Enrollment
6,150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphatic system neoplasm, malignant solid neoplasm